---
title: Real-time Automated Program for IDentification of VT Origin
nct_id: NCT03523286
overall_status: COMPLETED
phase: NA
sponsor: Amir AbdelWahab
study_type: INTERVENTIONAL
primary_condition: Ventricular Tachycardia
countries: Canada
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03523286.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03523286"
ct_last_update_post_date: 2023-02-08
last_seen_at: "2026-05-12T06:18:31.614Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Real-time Automated Program for IDentification of VT Origin

**Official Title:** Real-time Automated Program for IDentification of VT Origin - Pilot Study

**NCT ID:** [NCT03523286](https://clinicaltrials.gov/study/NCT03523286)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 8
- **Lead Sponsor:** Amir AbdelWahab
- **Collaborators:** Maritime Heart Centre
- **Conditions:** Ventricular Tachycardia, Ischemic Heart Disease
- **Start Date:** 2018-10-01
- **Completion Date:** 2022-05-01
- **CT.gov Last Update:** 2023-02-08

## Brief Summary

RAPID-VT Pilot is a single centre prospective cohort pilot study to assess the feasibility, safety and efficacy of catheter ablation of ventricular tachycardia (VT) guided by a novel real-time software to localize the origin of VT during the ablation procedure.

## Detailed Description

Consecutive patients with ischemic heart disease and clinical indication of VT ablation will undergo baseline clinical evaluation, echocardiography and cardiac CT imaging using a contrast-enhanced cardiac-gated method with a 64-section scanner. Trans-axial CT images comprising the whole heart volume will be exported in DICOM format. CT image processing will be performed and will be used to delineate the LV endocardial and/or epicardial geometries. These data will be imported into the RAPID-VT software and the 3D-electranatomical mapping system for image integration.

During the VT ablation procedure, VT(s) induction will be performed. The VT(s) 12-lead ECG will be acquired by the RAPID-VT software and will be localized to the scar margin using the RAPID-VT software. Catheter ablation will be attempted at software-determined sites.

Post procedure, patient will be followed up for a minimum of 6 months. That will include Remote ICD follow-up and telephone study visits. Follow-up at 6 months will include a clinic visit for assessment of heart failure status, ECG, ICD interrogation and changes in antiarrhythmic drug therapy.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients will be eligible for inclusion if they fulfilled VANISH inclusion criteria by having both of:

  1. Prior myocardial infarction (pathological Q waves or imaging evidence of regional myocardial akinesis/thinning in the absence of a non-ischemic cause)38 and
  2. One of the following VT events within the last 6 months while on Amiodarone or another class III or class I antiarrhythmic drug:

A: Sustained monomorphic VT documented on 12-lead ECG or rhythm strip requiring termination by pharmacologic means or DC cardioversion, B: ≥3 episodes of symptomatic VT treated with anti-tachycardia pacing (ATP), C: ≥1 appropriate ICD shocks, D: ≥3 VT episodes within 24 hours, separated by ≥ 5 minutes, E: sustained VT below detection rate of an ICD

Exclusion Criteria:

* Patients will be excluded from the trial if they:

  1. Are unable or unwilling to provide informed consent.
  2. Have active ischemia or another reversible cause of VT (e.g. drug-induced arrhythmia), or had recent acute coronary syndrome requiring revascularization.
  3. Are antiarrhythmic drug-naïve.
  4. Are known to have protruding left ventricular thrombus or mechanical aortic and mitral valves.
  5. Have had a prior catheter ablation procedure for VT.
  6. Are in renal failure (Creatinine clearance \<15 mL/min)
  7. Have NYHA Functional class IV heart failure or CCS Functional class IV angina.
  8. Have had recent ST elevation myocardial infarction (\< 1 month).
  9. Are pregnant or have a systemic illness likely to limit survival to \<1 year.
```

## Arms

- **RAPID-VT Software guided ablation** (EXPERIMENTAL) — The induced VT(s) 12-lead ECG will be acquired by the RAPID-VT software which will provide real time localization of the VT(s) exits from the scar margin. These exits will be targeted by ablation

## Interventions

- **RAPID-VT Software guided ablation** (OTHER) — Catheter ablation will target VT exit sites at scar margin as determined by the RAPID-VT software

## Primary Outcomes

- **Non-inducibility of VT** _(time frame: At end of ablation procedure)_ — Lack of any inducible VT at the end of the ablation procedure

## Secondary Outcomes

- **Procedure efficacy measure: VT(s) ablated** _(time frame: At end of procedure)_
- **Procedure efficacy measure: Procedure duration** _(time frame: At end of procedure)_
- **Procedure efficacy measure: VT recurrence** _(time frame: During follow up period of 6 months)_
- **Procedure safety measure: Acute complications** _(time frame: At end of procedure and at 30 days of follow up)_
- **Procedure safety measure: Clinical heart failure worsening** _(time frame: At end of procedure, at 30 days and 6 months of follow up)_
- **Procedure safety measure: Mortality and hospitalization for cardiac causes** _(time frame: At 30 days and 6 months of follow up)_

## Locations (1)

- QE II Health Sciences Centre, Halifax, Nova Scotia, Canada

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.qe ii health sciences centre|halifax|nova scotia|canada` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03523286.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03523286*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*